
1. malar j. 2014 aug 6;13:300. doi: 10.1186/1475-2875-13-300.

prevalence pfmdr1 alleles associated artemether-lumefantrine
tolerance/resistance maputo implementation of
artemisinin-based combination therapy.

lobo e(1), de sousa b, rosa s, figueiredo p, lobo l, pateira s, fernandes n,
nogueira f.

author information: 
(1)faculdade de medicina, departamento de ciênciasfisiológicas, universidade
eduardo mondlane, av salvador allende 702, maputo, moçambique.
loboelsa@yahoo.com.br.

background: mozambique implemented artemisinin-based combinations therapy (act)
using artemether-lumefantrine (al) first-line treatment uncomplicated 
malaria 2009. al remains highly efficacious, widespread use may soon
facilitate emergence artemisinin tolerance/resistance. prevalence of
pfmdr1 different alleles maputo mozambique known, either or
before introduction act. pfmdr1 molecular markers related plasmodium
falciparum susceptibility analysed transition act.
methods: first group samples collected june 2003 june 2005
and second group period march 2010 march 2012. three alleles
were analysed pcr-rflp: n86y, y184f d1246y, pfmdr1 gene.
results: alleles n86, 184f d1246 increased 19.5, 19.6 74.4% in
2003-2005 73.2, 22.7 96.7% 2010-2012, respectively. after
implementation act (2010-2012), pfmdr1 haplotypes, either two- three-codon
basis, generally less diverse implementation act
(2003-2005). prevalence haplotypes n86-184y, n86-d1246 184y-d1246
increased 12,2, 27.3 71.7% 2003-2005 59.4, 84.3 78.6% in
2010-2012. three-codon basis haplotypes nfd nyd also increased
significantly period.
conclusion: alleles n86 184 f triple haplotype n86-184 f-d1246
showed significantly increased prevalence introduction act.

doi: 10.1186/1475-2875-13-300 
pmcid: pmc4248432
pmid: 25098280  [indexed medline]

